Stockscreener 앱 받기
0.8798
2.85%
0.0244
시간 외 거래:
.87
-0.0098
-1.11%
전일 마감가:
$0.8554
열려 있는:
$0.87
하루 거래량:
405.51K
Relative Volume:
0.65
시가총액:
$95.95M
수익:
-
순이익/손실:
$-26.91M
주가수익비율:
-3.9991
EPS:
-0.22
순현금흐름:
$-19.57M
1주 성능:
+18.44%
1개월 성능:
+46.36%
6개월 성능:
-37.16%
1년 성능:
-47.00%
1일 변동 폭
$0.847
$0.8998
1주일 범위
$0.72
$0.9265
52주 변동 폭
$0.5526
$1.81
Atossa Therapeutics Inc Stock (ATOS) Company Profile
명칭
Atossa Therapeutics Inc
전화
206.588.0256
주소
10202 5TH AVENUE NE, SEATTLE, WA
ATOS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATOS
Atossa Therapeutics Inc
|
0.8798 | 95.95M | 0 | -26.91M | -19.57M | -0.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2018-01-26 | 개시 | Maxim Group | Buy |
Atossa Therapeutics Inc 주식(ATOS)의 최신 뉴스
Atossa Therapeutics and Ainos Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - guardonline.com
JPMorgan Chase & Co. Buys 211,654 Shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
ATOS: Atossa Therapeutics Secures New Patent for (Z)-endoxifen Formulations | ATOS Stock News - GuruFocus
A look into Atossa Therapeutics Inc (ATOS)’s deeper side - Sete News
LPL Financial LLC Cuts Stock Position in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
Atossa Therapeutics reports progress in breast cancer treatments - MSN
Atossa Therapeutics Inc (ATOS)’s results reveal risk - uspostnews.com
Atossa Therapeutics Inc (ATOS) rating initates by Maxim Group - knoxdaily.com
Sector Update: Health Care - marketscreener.com
Atossa Therapeutics (ATOS) Secures Patent for Key Breast Cancer Drug Formulations - GuruFocus
Atossa stock gains on U.S. patent win (ATOS:NASDAQ) - Seeking Alpha
Atossa Therapeutics Inc (ATOS) Stock: Navigating a Year of Volatility - investchronicle.com
Atossa Therapeutics Gets US Patent Covering (Z)-endoxifen Breast Cancer Treatment - marketscreener.com
Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281 - GuruFocus
Atossa Therapeutics (ATOS) Secures Patent for Innovative Drug Fo - GuruFocus
Atossa Therapeutics secures new patent for breast cancer drug By Investing.com - Investing.com India
Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio - The Manila Times
Atossa Therapeutics secures new patent for breast cancer drug - Investing.com Australia
Major Patent Breakthrough: Atossa's Cancer Drug Portfolio Expands with 58 New Protected Formulations - Stock Titan
Atossa Therapeutics Proposes Potentially Groundbreaking Study Ai - GuruFocus
Atossa Therapeutics (ATOS) Launches SMART 2.0 Phase 3 Clinical S - GuruFocus
Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025 - The Manila Times
Revolutionary Breast Cancer Prevention Trial Could Reduce Risk by 20% in High-Risk Women - Stock Titan
Hilton (NYSE:HLT) Reports Sales Below Analyst Estimates In Q1 Earnings - The Globe and Mail
Renaissance Technologies LLC Boosts Position in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
Stock Performance Spotlight: Atossa Therapeutics Inc (ATOS) Ends the Day at 0.73, Down by -0.73 - DWinneX
ATOS’s Market Quandary: Decoding the Ups and Downs of 2023 - investchronicle.com
Atossa Therapeutics announces issuance of U.S. patent - MSN
Ascendiant Capital Markets Comments on ATOS Q1 Earnings - Defense World
Atossa Therapeutics (NASDAQ:ATOS) Price Target Raised to $7.25 at Ascendiant Capital Markets - American Banking and Market News
What was Atossa Therapeutics Inc (ATOS)’s performance in the last session? - uspostnews.com
Plus Therapeutics Strengthens Board: Former Atossa CFO Brings 30 Years of NYSE and NASDAQ Leadership - Stock Titan
Atossa Therapeutics secures new patent for breast cancer treatment By Investing.com - Investing.com South Africa
Atossa Therapeutics (ATOS) Secures New U.S. Patent for (Z)-endoxifen Formulations - GuruFocus
Atossa Therapeutics secures new patent for breast cancer treatment - Investing.com
Atossa Therapeutics (ATOS) Secures Patent for New (Z)-endoxifen Formulation | ATOS Stock News - GuruFocus
Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio - The Manila Times
Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio | ATOS Stock News - GuruFocus
New Patent Strengthens Atossa's Breast Cancer Drug Portfolio: What This Means for Treatment Innovation - Stock Titan
Ascendiant Capital Markets Issues Positive Forecast for Atossa Therapeutics (NASDAQ:ATOS) Stock Price - Defense World
Atossa Therapeutics Inc’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - investchronicle.com
Atossa Therapeutics (ATOS) Partners with Nona Biosciences to Adv - GuruFocus
Nona Biosciences and Atossa Therapeutics Partner to Discover Nex - GuruFocus
Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer - The Manila Times
Atossa and Nona partner on antibody research for breast cancer - The Pharma Letter
Atossa Therapeutics (NASDAQ:ATOS) & Pharming Group (OTCMKTS:PHGUF) Critical Comparison - Defense World
Atossa Therapeutics says Intas Pharmaceuticals Filed Petition For Post Grant Review Against Co- SEC Filing - marketscreener.com
Atossa Therapeutics’ Earnings Call Highlights Cost Reductions and Clinical Progress - MSN
Charles Schwab Investment Management Inc. Lowers Stake in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
A closer look at Atossa Therapeutics Inc (ATOS)’s stock price trends - uspostnews.com
Atossa Therapeutics (ATOS) Projected to Post Quarterly Earnings on Monday - Defense World
Atossa Therapeutics Inc (ATOS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):